Xiaolun Huang

机构：Sichuan Cancer Hospital · ORCID：0000-0002-4993-0802

发表论文 87 篇 · 总被引 2328 次 · h-index 21

代表论文

• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 51)
• Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma (2024 · BMC Cancer · 被引 13)
• Single-Cell RNA Sequencing Revealed That the Enrichment of TPI1+ Malignant Hepatocytes Was Linked to HCC Metastasis and Immunosuppressive Microenvironment (2024 · Journal of Hepatocellular Carcinoma · 被引 5)
• Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective study (2025 · Frontiers in Immunology · 被引 3)
• Construction and validation of a novel liver function-tumor burden-inflammation-nutrition (LTIN) score for HCC patients underwent hepatectomy (2025 · BMC Cancer · 被引 3)
• Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis (2025 · BMC Cancer · 被引 3)